References
- Cairncross G, Wang M, Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31(3), 337–343 (2013).
- Gilbert MR, Wang M, Aldape K et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 29, 141s (2011).
- Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr. Gene Ther. 9(5), 422–427 (2009).
- Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin. Cancer Res. 18(20), 5537–5545 (2012).
- Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360(8), 765–773 (2009).
Websites
- Collaborative Ependymoma Research Network. www.cern-foundation.org
- Brain Tumor Trials Collaborative. www.bttconline.org